Daiichi Sankyo UK Ltd.

Grants

What is a Grant?

The term Grants applies to the provision of funding for actual goods and services given for the purpose of supporting healthcare, scientific research, or education. This is in response to an unsolicited request from a healthcare organisation, or those involved with the provision of healthcare, and must be provided without any implied or actual benefit in return for Daiichi Sankyo UK.

Grants to individuals are prohibited.

What are the criteria used to determine which grants are funded?

Daiichi Sankyo UK receives many requests for funding and may not be able to support all applications. Whilst all requests are considered, each request may not be successful.

Approval of funding requests are at the discretion of Daiichi Sankyo UK and requests for funding will be prioritised in our focus disease areas:

  • CVD prevention and management (which includes lipid management and Atrial Fibrillation)
  • General Adult Oncology (which includes Breast, Lung and Gastric cancers)

Daiichi Sankyo UK Ltd considers the following factors when evaluating which activities to support.

  • Does it support healthcare, scientific research, or education?
  • Does the project, initiative, or concept enhance patient care beyond that provided in routine practice within the NHS?
  • Does the application benefit and enable the NHS to improve care for patients, aim to reduce health inequalities, and is there a legacy associated with the project that will improve care provision over a longer term?
  • Does it meet the UK regulatory requirements of the Association of British Pharmaceutical Industry (ABPI) and Medicines and Healthcare products Regulatory Agency (MHRA)?

Disclosure and compliance

As a UK-based pharmaceutical company, Daiichi Sankyo UK adheres to the ABPI Code of Practice, including the requirements for annual disclosure of transfer of value for the corresponding period.

Details of each grant (transfer of value) must be publicly disclosed annually, giving in each case the financial amount or value and the name of the recipient institution, organisation, or association. Companies are also encouraged to ask recipients to make such funding public. Disclosure must be carried out in accordance with Clauses 28 and 29. Further information on public disclosures of transfer value from Daiichi Sankyo UK can be found on the Disclosure UK portal: https://search.disclosureuk.org.uk/

Application process

To apply for a grant from Daiichi Sankyo UK please download and complete the appropriate form. 

Please do not use the below forms to report adverse events.

For activities not covered by a DSUK Grant, please see the Q&A document below.

The relevant application forms are available below

Once completed, please email the fully completed form to Grantsanddonations@daiichi-sankyo.co.uk

 

Adverse Event Reporting 

Side effects (adverse events) should be reported Adverse Event Reporting | Daiichi Sankyo

 

UK/DSC/03/25/0004 March 2025

back to top